---
title: "VOR: Phase 3 telitacicept trials advance, cash runway extends to 2029, net loss narrows sharply"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295552479.md"
description: "Enrollment for Phase 3 trials of telitacicept in gMG and SjD is ongoing, with topline data for gMG expected in 1H27. Cash runway extends into early 2029, and net loss improved significantly year-over-year, driven by changes in warrant valuation.Original document: Vor Biopharma Inc. [VOR] SEC 8-K Current Report — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-11T14:38:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295552479.md)
  - [en](https://longbridge.com/en/news/295552479.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295552479.md)
generator: "portal-rs"
---

# VOR: Phase 3 telitacicept trials advance, cash runway extends to 2029, net loss narrows sharply

Enrollment for Phase 3 trials of telitacicept in gMG and SjD is ongoing, with topline data for gMG expected in 1H27. Cash runway extends into early 2029, and net loss improved significantly year-over-year, driven by changes in warrant valuation.

Original document: Vor Biopharma Inc. \[VOR\] SEC 8-K Current Report — Aug. 11 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VOR.US](https://longbridge.com/en/quote/VOR.US.md)

## Related News & Research

- [Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | VOR Stock News](https://longbridge.com/en/news/295545637.md)
- [Vor Biopharma reports Q2 results](https://longbridge.com/en/news/295613869.md)
- [Vor Bio Q2 FY26 net loss narrows to $62.8 million; R&D expenses drop to $25.9 million](https://longbridge.com/en/news/295544536.md)
- [Alibaba to sell gaming arm for US$1.5 billion in boost to AI pivot: Bloomberg](https://longbridge.com/en/news/296046350.md)
- [Canal Ventures CEO Matsuoka spotlights SQUEEZE’s AI-led push to lift hotel productivity at BIPROGY Forum 2026](https://longbridge.com/en/news/296041975.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**